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Plerixafor with granulocyte colony-stimulating factor (G-CSF) is effective for hematopoietic stem cell (HSC)
mobilization in patients with non-Hodgkin Lymphoma and myeloma; however, labeling requires dosing
11 hours before apheresis. Pharmacodynamic studies show peak blood CD34þ cell counts at 10 to 14 hours;
limited data are available for later time points. To address the effect of afternoonplerixafor dosing on CD34þ cell
yields,we conducted a prospective clinical trial inmyelomapatients undergoing stemcell collection. Thirty-one
patients received plerixafor 17 hours before apheresis; blood CD34þ cells were measured before the ﬁrst
plerixafor dose and 1, 3, and 17  1 hours after treatment. The target HSC number (10  106 CD34þ cells/kg)
was collected from 22 subjects (73%) in 1 day and from all subjects within 3 days. Hematopoietic engraftment
after transplantation and adverse events were similar to previous studies. Plerixafor given 17 hours before
apheresis yields desired HSC collection efﬁciencies after induction treatment in myeloma patients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION before apheresis (3:00 PM) would yield adequate CD34þ HSC
Plerixafor AMD3100, Mozobil, Genzyme Corporation,
Cambridge, MA) with granulocyte colony-stimulating factor
(G-CSF) has been approved by the FDA for hematopoietic
stem cell (HSC) mobilization in patients with non-Hodgkin
lymphoma (NHL) and multiple myeloma (MM) since 2008.
Plerixafor pharmacokinetics and pharmacodynamics are
well described, with linear, dose-dependent pharmacoki-
netics after subcutaneous (SC) administration. In patients,
peak plasma concentrations occur 30 minutes after injection
with an elimination half-life of 4.6 hours [1]. In pharmaco-
dynamic studies of plerixafor with G-CSF, peak numbers of
CD34þ cells in blood occur 10 to 14 hours after administra-
tion; however, data are limited in the 14- to 24- hour time
frame [2,3]. Plerixafor labeling requires administration
approximately 11 hours before apheresis, which translates
into dosing at 10:00 PM. This regimen yields a single-day
collection rate of 54% (6  106 CD34þ cells/kg) in patients
with MM [4]. The current timing is inconvenient for patients
and providers, requires additional health care resources, and
may place patients at risk of adverse events in a home
setting. These factors and the window between peak plasma
concentrations and peak CD34þ cell counts provide a ratio-
nale to assess whether altering plerixafor timing affects cell
yields. We hypothesized that plerixafor given 17 hoursdgments on page 1395.
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PATIENTS, MATERIALS, AND METHODS
The primary objective was to evaluate the proportion of patients who
collected 10  106 CD34þ cells/kg in a single day of apheresis after pler-
ixafor administration at 3:00 PM combined with 7.5 mg/kg G-CSF adminis-
tered SC BID (rounded to vials), compared with institutional historical data
with G-CSF alone. In a Simon’s 2-stage design, we enrolled MM patients
undergoing planned HSC mobilization with G-CSF and plerixafor. All
subjects received continuous G-CSF for 4 days followed by concurrent
plerixafor (0.24 mg/kg SC daily) on day 5 for up to 4 days beginning at 3:00
PM the day before the ﬁrst day of a planned large- volume (20 liter to 24 liter)
apheresis procedure beginning at 8:00 AM. The apheresis volume needed to
collect the target number of CD34þ cells was estimated based on subject
weight and peripheral CD34þ cell concentration. Blood samples for CD34þ
analysis were collected before the ﬁrst plerixafor dose and at 1, 3, and
17  1 hours, then daily before apheresis as needed. Patients continued to
receive daily G-CSF and plerixafor with a maximum of a total of 4 aphereses
until the target CD34þ cell dose was collected. For subjects who underwent
autologous stem cell transplantation (SCT), data on time to neutrophil and
platelet engraftment were collected. The study design and sample size were
based on a historical population at Emory using G-CSF alone, where the
proportion of MM patients collecting6 106 cells/kg CD34þ cells was 30%,
compared with the published rate of 54% with plerixafor [4,5]. The control
group (n ¼ 26) received the same G-CSF regimen. Twenty-four of 26 had 1
regimen before mobilization (median cycles ¼ 4; range, 2 to 8), 20 of 26
received lenalidomide, and no one received melphalan. A targeted power of
80% and a signiﬁcance of .05 yielded a requirement of 4 responses in 12
patients in the ﬁrst stage to proceed to an additional 19 in the second stage
(total, n ¼ 31), according to the Simon’s design [6].
RESULTS AND DISCUSSION
Thirty-one patients were evaluable for the primary
endpoint; 16 were male, and the median age was 59 years
(range, 40 to 70). The majority (n ¼ 29, 94%) had received
1 premobilization chemotherapy regimen; 2 subjects re-
ceived 2. Lenalidomide, bortezomib, and dexamethasone
Table 1
Myeloma Treatment and Radiation Exposure before Mobilization
Induction Regimen Total (n)
Lenalidomide, bortezomib, dexamethasone 20
Lenalidomide, dexamethasone 4
Bortezomib, thalidomide, dexamethasone 2
Bortezomib, dexamethasone 2
Bortezomib, pegylated liposomal doxorubicin 2
Bortezomib, thalidomide 1
Radiation site 6
Spine 4
Femur and sternum 1
Prostate 1
Table 2
Collection and Timing Results of Plerixafor Dosing 17 Hours before
Apheresis
Time to collect 10  106 CD34þ cells/kg
1 d 22 (71%)
2 d 8 (26%)
3 d 1 (3%)
Time to collect 6  106 CD34þ cells/kg
1 d 28 (90%)
2 d 2 (7%)
3 d 1 (3%)
Time from dosing to apheresis,
median (range), h
16.88 (16.08-18)
Day- 1 apheresis volume, median (range) 20.37 L (12.6-28)
Data are presented as n (%) unless otherwise indicated.
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a median of 4 (range, 1 to 6) cycles before cytokine mobili-
zation. Any lenalidomide-containing induction regimen was
used in 24 (77%). Six patients received prior radiation, and
prior treatment is summarized in Table 1. Data from
28 patients showed mean (SD) CD34þ cell counts in
peripheral blood pre-plerixafor and 1, 3, and 17 hours after
theﬁrst dose increased through the dosing interval (Figure 1).
The target number of CD34þ cells was collected in 1 day of
apheresis from 70% of subjects and from all subjects with
3 days of apheresis (Table 2). Of the 9 subjects requiringmore
than 1 day of apheresis, 5 had received prior radiation.
Ninety percent of patients collected 6  106 CD34þ cells/kg
in a single day. All patients received plerixafor more than
16 hours before initiating apheresis. Common adverse events
included grade 1/2 bone pain (58%), nausea (35%), injection
site reactions (32%), hypokalemia (23%), diarrhea (16%), and
dizziness (13%). Grade 3 bone pain and hypokalemia
occurred in 1 patient each. To date, 20 (65%) patients have
proceeded to autologous SCT with melphalan conditioning
and all have engrafted, with median time to an absolute
neutrophil count (ANC)  500/mm3 of 13 days (range, 11 to
15) and platelets 20,000/mm3 of 16 days (range, 11 to 21).
Plerixafor given 17 hours before apheresis initiation with
G-CSF 7.5 mg/kg SC BID after induction therapy inMMpatients
was effective, yielding  10  106 CD34þ cells/kg in >70% of
patients. Compared with historical institutional data with G-
CSF 7.5 mg/kg SC BID alone for 4 days in MM patients, where
the collection of 6  106 cells/kg CD34þ cells was 30%, we
achieved this number in 1 day in 90% of patients receiving the
combination. Most patients in this trial received 4 cycles of
lenalidomide-containing induction therapy, which has been
shown to impair mobilization of CD34þ cells when given for
prolonged periods [7]. The efﬁcacy of plerixafor 17 hours
before apheresis in a more heavily pretreated populationFigure 1. Day 1 peripheral CD34þ cell count increase after plerixafor dosing
(n ¼ 28).warrants further study. Pharmacodynamic data showed the
peripheral bloodCD34þ cell population increased throughout
the dosing interval, with a median 4.6-fold increase over pre-
plerixafor counts at 17 hours. Prediction of successful mobi-
lization based on peripheral blood CD34þ cell counts before
plerixafor administration has been evaluated; however, ﬁxed
thresholds (eg,10 cells/mL to 20 cells/mL) have not consistently
yielded adequate day- 1 collections, and study populations
have varied [8,9]. Although it is possible that a proportion of
patients in our study may have collected goal CD34þ cell
counts without plerixafor, it can be difﬁcult to prospectively
identify them based on pre-plerixafor peripheral CD34þ
counts from currently available data using cytokine-only
approaches [10]. Our target of 10  106 CD34þ cells/kg in
a single day of apheresis is also higher than the majority of
studies utilizing pre-plerixafor peripheral CD34þ counts to
determine need. Median times to neutrophil and platelet
engraftment after autologous SCT were 13 and 16 days,
respectively, which, although evaluated in a different
population, compares favorably with the 11 and 18 days
seen previously. The G-CSF regimen used in our evaluation
(15 mg/kg/day) differs from previous plerixafor studies and is
based on our institutional experience and trials showing
a positive dose-response relationship for CD34þ cell yields
above G-CSF doses of 10 mg/kg/day [11,12].
The earlier administration of plerixafor was also safe,
with adverse event rates likely attributable to the combina-
tion consistent with previous publications. The exceptions
were higher rates of bone pain and injection site reactions,
potentially due to higher G-CSF doses used. Serious adverse
events after plerixafor are rare and were not seen in our
population; however, if they occur, administration in a health
care environment during the day would allow intervention
by multiple clinicians.
Administration of plerixafor 17 hours before apheresis is
more convenient for patients and may obviate the need for
after- hours clinic operation or home health care nursing
visits, potentially reducing health care costs associated with
the combination. The alternative approach of delaying pler-
ixafor use until patients fail to collect or use of rescue pler-
ixafor may additionally increase overall health care costs by
increasing apheresis days, depending on threshold values of
total CD34þ cells/kg targeted.
Although our data are encouraging for earlier plerixafor
administration, it is important to recognize their limitations,
and they should not be extrapolated for use in other settings
(ie, lymphoma, more heavily pretreated myeloma patients,
or in combination with chemotherapy). In conclusion, our
data support plerixafor administration 17 hours (3:00 PM)
before the initiation of apheresis in myeloma patients with
limited prior therapy undergoing CD34þ cell mobilization.
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A rare, multisystem, plasma cell neoplasm, POEMS (polyradiculoneuropathy, organomegaly, endocrinopathy,
M-spike, skin changes) syndrome is characterized by an abundance of proinﬂammatory and angiogenic
cytokines. Patients with POEMS are known to have a high incidence of engraftment syndrome after autol-
ogous stem cell transplantation. We conducted a pilot study assessing levels of 30 different pro- and anti-
inﬂammatory cytokines before and serially after transplantation in 18 patients with plasma cell
neoplasms: POEMS syndrome (n ¼ 9), multiple myeloma (n ¼ 4), and amyloidosis (n ¼ 5). We show that
POEMS patients have higher pretransplantation levels of IL-4, IL-10, IL-13, IFN-a, and EGF as compared with
those with non-POEMS plasma cell neoplasms. Higher pre- and posttransplantation IL-13 levels correlated
with delayed neutrophil engraftment in POEMS patients. Low posttransplantation IL-1RA levels correlated
with engraftment syndrome in both POEMS and non-POEMS patients. We conclude that differences in the
peri-transplantation cytokine milieu may explain the higher transplantation morbidity in patients with
POEMS syndrome. Our results need validation in a larger cohort.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
POEMS syndrome (polyradiculoneuropathy, organo-
megaly, endocrinopathy, M-spike, skin changes) is a poorly
understood multisystem paraneoplastic disorder secondary
to a plasma cell neoplasm [1]. The hallmark of this complex
disease is the presence of angiogenic and proinﬂammatory
cytokines, such as vascular endothelial growth factor (VEGF),
IL-1b, IL-6, and TNF-a seen in patients with POEMS when
